{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Alzheimer\u2019s disease", "Crocus sativus L", "amyloidogenesis", "natural products", "protein aggregation inhibitors"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34233431", "DateCompleted": {"Year": "2021", "Month": "12", "Day": "07"}, "DateRevised": {"Year": "2021", "Month": "12", "Day": "14"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "12", "Day": "23"}], "Language": ["eng"], "ELocationID": ["10.1515/bmc-2020-0018"], "Journal": {"ISSN": "1868-503X", "JournalIssue": {"Volume": "11", "Issue": "1", "PubDate": {"Year": "2020", "Month": "Dec", "Day": "23"}}, "Title": "Biomolecular concepts", "ISOAbbreviation": "Biomol Concepts"}, "ArticleTitle": "Alzheimer's disease: exploring nature's 'medicinal chest' for new therapeutic agents.", "Pagination": {"StartPage": "201", "EndPage": "208", "MedlinePgn": "201-208"}, "Abstract": {"AbstractText": ["Natural products have served humanity as a valuable source for the discovery and development of therapeutic agents. In addition, these phytochemicals can function as lead compounds for the development of synthetic analogs aimed at treating human diseases. In our aging society, Alzheimer's disease (AD) is the most common cause of dementia, which is characterized by a significant and progressive loss of memory and other cognitive functions. As society demographics change, the predominance of AD and other age-related dementias is increasing, with concurrent financial and societal costs.AD represents one of the most remarkable scientific challenges for drug discovery as the search for effective disease-modifying agents has been unsuccessful. Medicinal plants have been used for their \"anti-aging\" properties, and cognitive enhancing properties. In the past decades, natural products have been studied for their anti-AD properties, and their potential for developing therapeutic agents against several molecular targets has been evaluated. This insight evaluates the prospects of medicinal plants for providing disease-modifying, as well as disease-preventing, agents for AD."], "CopyrightInformation": "\u00a9 2020 Anthony Tsarbopoulos, published by De Gruyter."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "National and Kapodistrian University of Athens Medical School, Department of Pharmacology, Athens, Greece, Athens 11527, Greece."}, {"Identifier": [], "Affiliation": "GAIA Research Center, Bioanalytical Department, The Goulandris Natural History Museum, Kifissia14562, Greece."}], "LastName": "Tsarbopoulos", "ForeName": "Anthony", "Initials": "A"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "Biomol Concepts", "NlmUniqueID": "101518829", "ISSNLinking": "1868-5021"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Biological Products"}, {"RegistryNumber": "0", "NameOfSubstance": "Phytochemicals"}], "MeshHeadingList": [{"QualifierName": ["drug therapy"], "DescriptorName": "Alzheimer Disease"}, {"QualifierName": ["chemistry", "therapeutic use"], "DescriptorName": "Biological Products"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry", "therapeutic use"], "DescriptorName": "Phytochemicals"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Patterson C. The state of the art of dementia research: New frontiers. World Alzheimer Report, 2018 (accessed September, 2018)."}, {"Citation": "H\u00fcgel HM, Jackson N. Polyphenols for the prevention and treatment of dementia diseases. Neural Regen Res. 2015 Nov;10(11):1756\u20138."}, {"Citation": "Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013 May;80(19):1778\u201383."}, {"Citation": "Etters L, Goodall D, Harrison BE. Caregiver burden among dementia patient caregivers: a review of the literature. J Am Acad Nurse Pract. 2008 Aug;20(8):423\u20138."}, {"Citation": "Choi DY, Lee YJ, Hong JT, Lee HJ. Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer\u2019s disease. Brain Res Bull. 2012 Feb;87(2-3):144\u201353."}, {"Citation": "Long JM, Holtzman DM. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell. 2019 Oct;179(2):312\u201339."}, {"Citation": "Chen XQ, Mobley WC. Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric A\u03b2 and Tau Species. Front Neurosci. 2019 Jun;13:659."}, {"Citation": "Dos Santos Picanco LC, Ozela PF, de Fatima de Brito Brito M, Pinheiro AA, Padilha EC, Braga FS, et al. Alzheimer\u2019s Disease: A Review from the Pathophysiology to Diagnosis, New Perspectives for Pharmacological Treatment. Curr Med Chem. 2018;25(26):3141\u201359."}, {"Citation": "Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of \u03b2-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012 Jan;69(1):98\u2013106."}, {"Citation": "Panza F, Lozupone M, Logroscino G, Imbimbo BP. A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019 Feb;15(2):73\u201388."}, {"Citation": "Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006189."}, {"Citation": "Hardy JA, Higgins GA. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992 Apr;256(5054):184\u20135."}, {"Citation": "Lovestone S, Reynolds CH. The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience. 1997 May;78(2):309\u201324."}, {"Citation": "Bourdenx M, Koulakiotis NS, Sanoudou D, Bezard E, Dehay B, Tsarbopoulos A. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: examples of amyloidopathies, tauopathies and synucleinopathies. Prog Neurobiol. 2017 Aug;155:171\u201393."}, {"Citation": "Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer\u2019s disease. Lancet. 2011 Mar;377(9770):1019\u201331."}, {"Citation": "Prusiner SB. Cell biology. A unifying role for prions in neurodegenerative diseases. Science. 2012 Jun;336(6088):1511\u20133."}, {"Citation": "Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer\u2019s disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999 Feb;66(2):137\u201347."}, {"Citation": "Lipton SA. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets. 2007 May;8(5):621\u201332."}, {"Citation": "Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al. Reducing endogenous tau ameliorates amyloid \u03b2-induced deficits in an Alzheimer\u2019s disease mouse model. Science. 2007 May;316(5825):750\u20134."}, {"Citation": "Bloom GS. Amyloid-\u03b2 and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014 Apr;71(4):505\u20138."}, {"Citation": "Giacobini E, Becker RE. One hundred years after the discovery of Alzheimer\u2019s disease. A turning point for therapy? J Alzheimers Dis. 2007 Aug;12(1):37\u201352."}, {"Citation": "Becker RE, Greig NH. Increasing the success rate for Alzheimer\u2019s disease drug discovery and development. Expert Opin Drug Discov. 2012 Apr;7(4):367\u201370."}, {"Citation": "Walter J, Haass C. Secretases as Targets for \u03b2-Amyloid Lowering Drugs. Drug Dev Res. 2002;56(2):201\u201310."}, {"Citation": "Giacobini E, Becker RE. One hundred years after the discovery of Alzheimer\u2019s disease. A turning point for therapy? J Alzheimers Dis. 2007 Aug;12(1):37\u201352."}, {"Citation": "Chesneau V, Vekrellis K, Rosner MR, Selkoe DJ. Purified recombinant insulin-degrading enzyme degrades amyloid \u03b2-protein but does not promote its oligomerization. Biochem J. 2000 Oct;351(Pt 2):509\u201316."}, {"Citation": "Lahiri DK, Farlow MR, Greig NH, Sambamurti K. Current Drug Targets for Alzheimer\u2019s Disease Treatment. Drug Dev Res. 2002;56(3):267\u201381."}, {"Citation": "Lansbury PT Jr. Following nature\u2019s anti-amyloid strategy. Nat Biotechnol. 2001 Feb;19(2):112\u20133."}, {"Citation": "Lansbury PT Jr. Back to the future: the \u2018old-fashioned\u2019 way to new medications for neurodegeneration. Nat Med. 2004 Jul;10(S7 Suppl):S51\u20137."}, {"Citation": "Graham WV, Bonito-Oliva A, Sakmar TP. Update on Alzheimer\u2019s Disease Therapy and Prevention Strategies. Annu Rev Med. 2017 Jan;68(1):413\u201330."}, {"Citation": "Walsh DM, Klyubin I, Fadeeva JV, Rowan MJ, Selkoe DJ. Amyloid-\u03b2 oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans. 2002 Aug;30(4):552\u20137."}, {"Citation": "Wirths O, Multhaup G, Bayer TA. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide\u2014the first step of a fatal cascade. J Neurochem. 2004 Nov;91(3):513\u201320."}, {"Citation": "Lesn\u00e9 S, Kotilinek L. Amyloid plaques and amyloid-beta oligomers: an ongoing debate. J Neurosci. 2005 Oct;25(41):9319\u201320."}, {"Citation": "Panza F, Lozupone M, Logroscino G, Imbimbo BP. A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019 Feb;15(2):73\u201388."}, {"Citation": "Panza F, Lozupone M, Seripa D, Imbimbo BP. Amyloid-\u03b2 immunotherapy for alzheimer disease: is it now a long shot? Ann Neurol. 2019 Mar;85(3):303\u201315."}, {"Citation": "Biogen News Release October 22, 2019."}, {"Citation": "Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461\u201377."}, {"Citation": "Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr. 2010 Mar;10(1):14."}, {"Citation": "Myers N, Mittermeier RA, Mittermeier CG, da Fonseca GA, Kent J. Biodiversity hotspots for conservation priorities. Nature. 2000 Feb;403(6772):853\u20138."}, {"Citation": "Reid WV. Biodiversity hotspots. Trends Ecol Evol. 1998 Jul;13(7):275\u201380."}, {"Citation": "Blandini F. Neural and immune mechanisms in the pathogenesis of Parkinson\u2019s disease. J Neuroimmune Pharmacol. 2013 Mar;8(1):189\u2013201."}, {"Citation": "Howes MJ, Perry NS, Houghton PJ. Plants with traditional uses and activities, relevant to the management of Alzheimer\u2019s disease and other cognitive disorders. Phytother Res. 2003 Jan;17(1):1\u201318."}, {"Citation": "Koulakiotis NS, Anagnostopoulos D, Chalatsa I, Sanoudou D, Tsarbopoulos A. Natural Products as Sources of Potential Antiamyloidogenic Agents. J. Adv. Med. Res. 2015;1(3):10\u20137."}, {"Citation": "Colciaghi F, Borroni B, Zimmermann M, Bellone C, Longhi A, Padovani A, et al. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiol Dis. 2004 Jul;16(2):454\u201360."}, {"Citation": "Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci. 2005 Sep;25(38):8807\u201314."}, {"Citation": "Jia Y, Wang N, Liu X. Resveratrol and Amyloid-Beta: mechanistic Insights. Nutrients. 2017 Oct;9(10):1122\u201334."}, {"Citation": "Bastianetto S, Zheng WH, Quirion R. Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons. Br J Pharmacol. 2000 Oct;131(4):711\u201320."}, {"Citation": "Moussa C, Hebron M, Huang X, Ahn J, Rissman RA, Aisen PS, et al. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer\u2019s disease. J Neuroinflammation. 2017 Jan;14(1):1\u201310."}, {"Citation": "Fujiwara H, Tabuchi M, Yamaguchi T, Iwasaki K, Furukawa K, Sekiguchi K, et al. A traditional medicinal herb Paeonia suffruticosa and its active constituent 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranose have potent anti-aggregation effects on Alzheimer\u2019s amyloid beta proteins in vitro and in vivo. J Neurochem. 2009 Jun;109(6):1648\u201357."}, {"Citation": "Park SY. Potential therapeutic agents against Alzheimer\u2019s disease from natural sources. Arch Pharm Res. 2010 Oct;33(10):1589\u2013609."}, {"Citation": "Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. Mediterranean diet and mild cognitive impairment. Arch Neurol. 2009 Feb;66(2):216\u201325."}, {"Citation": "Bazoti FN, Tsarbopoulos A, Markides KE, Bergquist J. Study of the non-covalent interaction between amyloid-\u03b2-peptide and melatonin using electrospray ionization mass spectrometry. J Mass Spectrom. 2005 Feb;40(2):182\u201392."}, {"Citation": "Bazoti FN, Bergquist J, Markides K, Tsarbopoulos A. Detection of the Non-Covalent Complex between Amyloid-\u03b2 Peptide (1-40) and Oleuropein using Electrospray Ionization Mass Spectrometry. J Am Soc Mass Spectrom. 2006;17:568\u201375."}, {"Citation": "Bazoti FN, Bergquist J, Markides K, Tsarbopoulos A. Localization of the Binding Site in the Non-Covalent Interaction between Amyloid-\u03b2 Peptide (1-40) and Oleuropein Using Electrospray Ionization FTICR Mass Spectrometry. J Am Soc Mass Spectrom. 2008;19:1078\u201385."}, {"Citation": "Galanakis P, Bazoti F, Bergquist J, Markides K, Spyroulias G, Tsarbopoulos A. Study of the Interaction between the Amyloid Beta Peptide A\u03b2 (1-40) and Antioxidant Compounds by NMR Spectroscopy. Biopolymers:Peptide Science. 2011;96:316\u201327."}, {"Citation": "Koulakiotis NS, Anagnostopoulos D, Chalatsa I, Sanoudou D, Tsarbopoulos A. (2014). \u201cUsing Biodiversity for Discovering Potential Anti-Amyloidogenic Agents\u201d, in Proceedings of the PHARMA2014 Conference, Singapore, pp. 60\u201363."}, {"Citation": "Chalatsa I, Arvanitis DA, Koulakiotis NS, Giagini A, Skaltsounis AL, Papadopoulou-Daifoti Z, et al. The Crocus sativus compounds trans-crocin 4 and trans-crocetin modulate the amyloidogenic pathway and tau misprocessing in Alzheimer disease neuronal cell culture models. Front Neurosci. 2019 Mar;13(249):1-15."}, {"Citation": "Karkoula E, Lemonakis N, Kokras N, Dalla C, Gikas E, Skaltsounis AL, et al. Trans-crocin 4 is not hydrolyzed to crocetin following i.p. administration in mice, while it shows penetration through the blood brain barrier. Fitoterapia. 2018 Sep;129:62\u201372."}, {"Citation": "Koulakiotis NS, Purhonen P, Gikas E, Hebert H, Tsarbopoulos A. Crocus-derived compounds alter the aggregation pathway of Alzheimer\u2019s Disease: associated beta amyloid protein. Sci Rep. 2020 Oct;10(1):18150."}, {"Citation": "Maalouf M, Rho JM, Mattson MP. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev. 2009 Mar;59(2):293\u2013315."}, {"Citation": "Scarmeas N, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, Tang MX, et al. Physical activity, diet, and risk of Alzheimer disease. JAMA. 2009 Aug;302(6):627\u201337."}, {"Citation": "Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. Mediterranean diet and mild cognitive impairment. Arch Neurol. 2009 Feb;66(2):216\u201325."}, {"Citation": "Anastasiou CA, Yannakoulia M, Kosmidis MH, Dardiotis E, Hadjigeorgiou GM, Sakka P, et al. (2017). Mediterranean diet and cognitive health: Initial results from the Hellenic Longitudinal Investigation of Ageing and Diet. PLoS ONE 12(8): e0182048 (doi.org/https://doi.org/10.1371/journal.pone.0182048)."}], "ReferenceList": [], "Title": "References"}], "History": [{"Year": "2020", "Month": "10", "Day": "22"}, {"Year": "2020", "Month": "11", "Day": "16"}, {"Year": "2021", "Month": "7", "Day": "8", "Hour": "3", "Minute": "5"}, {"Year": "2021", "Month": "7", "Day": "9", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "12", "Day": "15", "Hour": "6", "Minute": "0"}], "PublicationStatus": "epublish", "ArticleIdList": ["34233431", "10.1515/bmc-2020-0018", "bmc-2020-0018"]}}], "PubmedBookArticle": []}